Kumar A; Sharma M; Su Y; Singh S; Tanley JE; Casanova R; Hsu FC; Craft S; Mielke MM; Hughes TM; Deep G · 2026 · Alzheimer's & dementia : the journal of the Alzheimer's Association
Paper
INTRODUCTION: Blood-based biomarkers are essential for early detection, monitoring, and therapeutic development in Alzheimer's disease (AD) and related dementia (ADRD), but current assays lack brain cell specificity and sensitivity to low-abundant proteins. METHOD: We isolated the following brain cell-derived small extracellular vesicles (sEV) from the plasma of individuals with normal cognition (CN), mild cognitive impairment (MCI), or ADRD: neurons (NDE), astrocytes (ADE), microglia (MDE), oligodendrocytes (ODE), pericytes (PDE), and endothelial cells (EDE). Using NULISAseq, we profiled 122 proteins, spanning AD pathology, neurodegeneration, and neuroinflammation. RESULTS: sEV proteomes showed distinct brain cell-type-specific signatures. MCI exhibited early dysregulation of neuroprotective, inflammatory, and vascular markers in NDE, MDE, and ODE. ADRD displayed broader alteration tau, amyloid, neuroinflammation, vascular dysfunction, and synaptic loss across multiple sEV populations. DISCUSSION: Combining NULISAseq with brain cell-derived plasma sEV enables the detection of multicellular molecular changes in ADRD, supporting their use as a minimally invasive platform for biomarker discovery.
Analysis
Preparing paper insights from the available abstract and paper details.
Discovery
Chih-Ching Wu; Wei-Hsiang Huang; Ya-Pei Chang
Sharyn L. Rossi; Diane E. Bovenkamp
Sekita A; Sprügel MI; Balk S; Haupenthal D; Engelhorn T; Schmidt MA; Doerfler A; Oberstein TJ; Maler JM; Kornhuber J; Lewczuk P; Rothhammer V; Schwab S; Kuramatsu JB; Sembill JA
Pollard C; Miller R; Stirland I; Keni M; Jenkins A; Saito E; Hill JT; Jenkins T
Mishra R; Chauhan N; Agrawal KK
MayaRae N Mugosa; Jefferson W Kinney; Lorenzo Gabriel Pasia; Mason Jonah; Isabella Hou; Aaron Ritter
Source record